#hpapimarket

[healthcare-industry-research]

[216 Pages Report] The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 16.49 Billion in 2017, at a CAGR 8.7%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023.

The HPAPI market is fragmented market with the presence of several small and big players. Prominent players in this market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland).

[healthcare-industry-research]

High Potency APIs: Global Industry Outlook | Different Strategies Adopted by Major Leaders

The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, i...

The HPAPI market is fragmented market with the presence of several small and big players. Prominent players in this market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland).